Emmes Acquires Rare-Disease CRO Casimir

Published on: 

Emmes has acquired Casimir, marking its fourth major acquisition.

Emmes, a global clinical research organization (CRO) headquartered in Maryland, announced on March 10, 2022 that it has acquired Casimir, a Massachusetts-based CRO. The acquisition marks Emmes’ fourth major acquisition in just over a year.

Casimir focuses on outcome measures of disease progression and treatment benefits and has experience in more than 20 rare diseases. It is specifically known for its efforts in remote data capture for Duchenne Muscular Dystrophy (DMD) using its Duchenne Video Assessment tool, which is also being used to explore a variety of other neurogenerative/neuromuscular diseases.

Emmes also prioritizes the research of rare diseases, establishing the Orphan Reach Emmes’ Rare Disease center for drug development and clinical research. The acquisition of Casimir further establishes Emmes as a leading CRO in rare and orphan diseases and expands its research and development capabilities.


“The combination of Emmes and Casimir will provide our clients access to full-service protocol design, strategy and trial execution services, not only for rare diseases, such as DMD, but also for a variety of myopathies and neurological conditions,” commented Rhonda Henry, president of Emmes’ BioPharma Group. “Casimir is known for its virtual clinical trials and remote assessments that minimize the burden on patients and caregivers. This is something that we will build upon in other Emmes studies, as our goal is to utilize more and more real-world evidence to improve data quality and information for doctors when treating their patients.”

Source: Emmes